MavriX Bio Commences First Patient Administration in ASCEND-AS Trial for MVX-220 Gene Therapy Targeting Angelman Syndrome MavriX Bio has commenced dosing its first patient in the clinical trial for MVX-220, a groundbreaking gene therapy aimed at treating Angelman Syndrome, with FDA support.

MavriX Bio Commences First Patient Administration in ASCEND-AS Trial for MVX-220 Gene Therapy Targeting Angelman Syndrome #United_States #Middleton #Angelman_Syndrome #MVX-220 #MavriX_Bio

MavriX Bio's MVX-220 Gains FDA Fast Track Status for Angelman Syndrome Treatment MavriX Bio has secured FDA's Fast Track designation for MVX-220, aimed at treating Angelman syndrome. This status underscores the urgency for effective therapies in this area.

MavriX Bio's MVX-220 Gains FDA Fast Track Status for Angelman Syndrome Treatment #United_States #Middleton #Angelman_Syndrome #MVX-220 #MavriX_Bio